Portfolios and Safety - Esthetician Leadership Today

U.S. FDA Approves Celltrion’s STELARA Biosimilar

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). . immunology market.”

Portfolios

Portfolios Injections Office Safety

PHysicians & the esthetician

Southeastern Esthetics Institute

AUGUST 23, 2016

Specific courses for cosmetic lasers, for example, are crucial to add to the esthetics portfolio, in order to showcase added training beyond that of the esthetics fundamentals course. Esthetics practitioners within any advanced setting should obtain certifications underneath their license for each individual advanced procedure.

Esthetician

Esthetician Esthetics Document Office

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

The Dermatology Digest

MARCH 5, 2024

The Allergan Medical Institute (AMI) team can train aesthetic providers on safe and effective treatments using the Allergan Aesthetics portfolio to address 90% of the face.

Portfolios

Portfolios Injections Training Facials

FDA OKs Emergent’s mPox Vaccine

The Dermatology Digest

AUGUST 30, 2024

The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure.

Portfolios

Portfolios Tools Eczema Safety

FDA Nod for Ustekinumab Biosimilar

The Dermatology Digest

SEPTEMBER 30, 2024

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris. and worldwide.

Portfolios

Portfolios Partnerships Marketing Safety

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

The Dermatology Digest

SEPTEMBER 9, 2024

“China has always been a strategic market for Sisram, and the approval of Daxxify serves as a key milestone for bringing Sisram’s high-end injectables portfolio to Mainland China,” says Mr. Liu Yi, Sisram Chairman and Executive Director, in a news release.

Portfolios

Portfolios Dermatology Injections Marketing

Arch Amenities’ Catherine Warren on technology & creating memorable experiences.

Spa Executive

JULY 17, 2024

This includes expanding our portfolio of touchless and AI-driven wellness solutions that enhance guest experiences while prioritizing safety and hygiene. As we navigate the post-pandemic landscape, there’s a growing emphasis on integrating advanced technologies and sustainable practices into our offerings.

Technology

Technology Hospital Sustainability Innovations

How To Become A Beauty Educator In Arizona

The Studio Academy of Beauty

MAY 31, 2023

The practical exam, on the other hand, assesses your technique, professionalism, and adherence to safety protocols, ensuring that you can effectively demonstrate and teach these skills to your students. Attend review classes and workshops to understand the material better and enhance your overall preparation.

Education

Education Continuous Education Continuing Education Portfolios

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

The Dermatology Digest

MARCH 5, 2024

The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate the safety and PK of APG777 in healthy volunteers. The study enrolled 40 healthy adult participants into three single-ascending dose (SAD) and two multiple-ascending dose (MAD) cohorts.

Injections

Injections Safety Sustainability Clinic

“From Novice to Expert: How Injectable Training Courses Can Elevate Your Skills.”

AAAMS

APRIL 18, 2024

This comprehensive knowledge ensures not only the safety and satisfaction of patients but also elevates the provider’s reputation, setting the groundwork for a thriving practice. You’ll also learn to assess a client’s face, plan treatment strategies, and ensure safety to avoid complications.

Injections

Injections Training Legal Facials

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

The Dermatology Digest

JULY 1, 2024

The FDA’s approval of PYZCHIVA is based on a totality of evidence including analytical, non-clinical and clinical data demonstrating biosimilarity to Stelara, with no clinically meaningful differences in terms of safety, purity and potency.

Portfolios

Portfolios Safety Clinic Injections

10 Best Nasal Sprays for COVID-19 (2023)

Aesthetics Advisor

SEPTEMBER 15, 2023

The pharmacology, toxicity, and safety data for NO use in humans has been well-established for decades. For a full list of Marinomed’s portfolio of Carragelose® containing nasal sprays and oral products, please visit [link] , for a list of scientific publications on Carragelose®, [link].

Hospital

Hospital Clinic Marketing Medical

"Safe" Beauty E-Summit 2022 Replay!

The Eco Well Blog

SEPTEMBER 18, 2022

There, he led the Product Safety group for 25 years. His product safety portfolio included: Jergens and Curel lotions, Biore face care, Ban antiperspirant, and John Frieda hair care. As a result, the products being developed met the expected safety standards and regulatory requirements upon launch.

Branding

Branding Safety Management Marketing

2023 Sunscreen E-Summit Replay

The Eco Well Blog

MAY 8, 2023

He’s held key R&D, regulatory, quality, product safety, clinical & scientific affairs positions at Ciba, Dial, Henkel, ITG Brands, Newell Rubbermaid. He’s been active in helping shape & influence Congressional cosmetic and OTC drug legislative reform initiatives.

Legal

Legal Technology Sun Protection Branding

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections

Injections Medical Portfolios Branding

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13.

Portfolios

Portfolios Dermatitis Sustainability Injections

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

The Dermatology Digest

MARCH 27, 2025

ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions. Patients completing Week 24 will have the opportunity to participate in a long-term extension (LTE) trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.

Pharmaceutical

Pharmaceutical Portfolios Clinic Safety

U.S. FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.05% (Zoryve) for Children Aged 2 to 5 with Mild-to-moderate AD; PDUFA Date Set

The Dermatology Digest

FEBRUARY 26, 2025

The data highlight the efficacy of the cream, along with its favorable safety and tolerability profile, which are critical when prescribing a long-term treatment for children with AD, says Mercedes E. In clinical trials, investigational ZORYVE cream 0.05% has shown significant positive results in treating AD in children 2 to 5 years old.

Safety

Safety Dermatitis Portfolios Clinic

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. s Evolyssecollection.

Injections

Injections Portfolios Innovations Safety

Sunscreen E-Summit 2022: Replay

The Eco Well Blog

MAY 16, 2022

Next up, we’ll be tackling the topic of safety, coming your way in late September. serves as Environmental Scientist at Personal Care Products Council (PCPC) and focuses on assessing the environmental safety of cosmetics and personal care ingredients. This was our attempt to democratize accurate information for the cosmetics industry.

Legal

Legal Pharmaceutical Sun Protection Technology

Esthetician Leadership Today

U.S. FDA Approves Celltrion’s STELARA Biosimilar

PHysicians & the esthetician

Trending Sources

FDA Approves JUVÉDERM VOLUMA XC for Filling Temple Hollows

FDA OKs Emergent’s mPox Vaccine

FDA Nod for Ustekinumab Biosimilar

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology in the U.S. and Abroad

Arch Amenities’ Catherine Warren on technology & creating memorable experiences.

How To Become A Beauty Educator In Arizona

Topline Phase 1 Trial Results for Apogee’s APG777 in AD “Exceed Expectations”

“From Novice to Expert: How Injectable Training Courses Can Elevate Your Skills.”

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

10 Best Nasal Sprays for COVID-19 (2023)

"Safe" Beauty E-Summit 2022 Replay!

2023 Sunscreen E-Summit Replay

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

Inside the Apogee Pipeline: Company Shares Updates on APG777 and APG990 for AD

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

U.S. FDA Accepts sNDA for Arcutis’ Roflumilast Cream 0.05% (Zoryve) for Children Aged 2 to 5 with Mild-to-moderate AD; PDUFA Date Set

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

Sunscreen E-Summit 2022: Replay

Stay Connected